500 Mg Abiraterone Acetate Tablets IP

Name: 500 Mg Abiraterone Acetate Tablets IP
Brand: NEETCO BIOPHARMA
Price: 12000 INR
Availability: InStock

Price 12000 INR/ Bottle

Get a Price/Quote

MOQ : 1 Bottle

500 Mg Abiraterone Acetate Tablets IP Specification

Indication
Used in the treatment of metastatic castration-resistant prostate cancer

Salt Composition
Abiraterone Acetate 500 mg

Dosage Form
Tablet

Enzyme Types
Non-enzymatic pharmaceutical

Feature
Highly potent, selective CYP17 inhibitor

Ingredients
Abiraterone Acetate and Excipients

Application
Oral administration for prostate cancer

Physical Color/Texture
White to off-white, film-coated tablets

Fermentation Smell
Odorless

Storage Instructions
Store below 30C, protect from moisture

Shelf Life
24 Months

Contraindications
Not for use in women or children

Route of Administration
Oral

Packaging Size
120 tablets per bottle

Marketed By
As per pharmaceutical label details

Tablet Size and Shape
Oval, film-coated

Minimum Order Quantity
1 bottle (as per supplier)

Therapeutic Class
Antineoplastic agent

Drug Approval
Approved for medical use

CAS Number
154229-18-2

Strength
500 mg per tablet

Gender Target
Male

Warnings
To be used under strict medical supervision

Prescription Requirement
Prescription only

Controlled Substance
No

Product Code
May vary by supplier

About 500 Mg Abiraterone Acetate Tablets IP

Order Today and step into the kingly spotlight of advanced prostate cancer therapy with 500 Mg Abiraterone Acetate Tablets IP. These triumphant antineoplastic agents are famed for their efficacy in treating metastatic castration-resistant prostate cancer. Each oval, film-coated tablet delivers a potent 500 mg dose, ensuring instant savings with every bottle of 120 tablets. Exclusively for males, this prescription-only medication is distributed by renowned suppliers and offers selective CYP17 inhibition for optimal therapeutic results. Shelf life extends to 24 months, and the product features an odorless, white to off-white appearance. Minimum order: 1 bottle.

Therapeutic Use and Key Features

500 Mg Abiraterone Acetate Tablets IP is suitable for male patients diagnosed with metastatic castration-resistant prostate cancer. It is used under medical supervision as a highly potent, selective CYP17 inhibitor that targets cancer progression. The tablets are oval, film-coated, and odorless, ensuring easy oral administration and patient comfort. This famed antineoplastic agent comes in bottles of 120 tablets, each delivering 500 mg strength for effective cancer management, supporting a triumphant treatment plan.

Payment Terms and Delivery Details

Payment options for 500 Mg Abiraterone Acetate Tablets IP may include advance, premium rate settlements, or listed prices, as specified by the distributor. Sample availability is subject to supplier terms. The delivery time is planned for efficiency, depending on order confirmation and location. Each transaction ensures high standards in packaging and careful shipment of your prescription order, highlighting instant savings for bulk or single-bottle purchases to elevate your procurement experience.

FAQ's of 500 Mg Abiraterone Acetate Tablets IP:

Q: How should 500 Mg Abiraterone Acetate Tablets IP be administered?

A: The tablets are designed for oral use, as directed by a physician, typically accompanying other medications and closely monitored for therapeutic effect.

Q: What is the minimum order quantity for these tablets?

A: The minimum order quantity is one bottle containing 120 tablets, though bulk purchases may offer instant savings based on supplier rate.

Q: When should patients use Abiraterone Acetate Tablets IP?

A: Patients should use these tablets only upon prescription, after being diagnosed with metastatic castration-resistant prostate cancer, and under the strict supervision of a healthcare professional.

Q: Where are these tablets commonly distributed?

A: 500 Mg Abiraterone Acetate Tablets IP are distributed, exported, and supplied by pharmaceutical traders across India, as indicated on product labels.

Q: What are the main therapeutic benefits of this product?

A: This medication offers selective CYP17 inhibition, acting as a highly potent agent in the treatment of advanced prostate cancer, thereby supporting improved patient outcomes.